Literature DB >> 16322480

Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes.

Dirk Kienle1, Axel Benner, Alexander Kröber, Dirk Winkler, Daniel Mertens, Andreas Bühler, Till Seiler, Ulrich Jäger, Peter Lichter, Hartmut Döhner, Stephan Stilgenbauer.   

Abstract

The mutation status and usage of specific VH genes such as V3-21 and V1-69 are potentially independent pathogenic and prognostic factors in chronic lymphocytic leukemia (CLL). To investigate the role of antigenic stimulation, we analyzed the expression of genes involved in B-cell receptor (BCR) signaling/activation, cell cycle, and apoptosis control in CLL using these specific VH genes compared to VH mutated (VH-MUT) and VH unmutated (VH-UM) CLL not using these VH genes. V3-21 cases showed characteristic expression differences compared to VH-MUT (up: ZAP70 [or ZAP-70]; down: CCND2, P27) and VH-UM (down: PI3K, CCND2, P27, CDK4, BAX) involving several BCR-related genes. Similarly, there was a marked difference between VH unmutated cases using the V1-69 gene and VH-UM (up: FOS; down: BLNK, SYK, CDK4, TP53). Therefore, usage of specific VH genes appears to have a strong influence on the gene expression pattern pointing to antigen recognition and ongoing BCR stimulation as a pathogenic factor in these CLL subgroups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322480     DOI: 10.1182/blood-2005-04-1483

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

2.  Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells.

Authors:  Laurent D Vallat; Yuhyun Park; Cheng Li; John G Gribben
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

3.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

Review 4.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

5.  CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes.

Authors:  David Gonzalez; Monica Else; Dorte Wren; Monica Usai; Anne Mette Buhl; Anton Parker; David Oscier; Gareth Morgan; Daniel Catovsky
Journal:  Haematologica       Date:  2012-08-16       Impact factor: 9.941

6.  Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.

Authors:  Dirk Kienle; Axel Benner; Carolin Läufle; Dirk Winkler; Christof Schneider; Andreas Bühler; Thorsten Zenz; Annett Habermann; Ulrich Jäger; Peter Lichter; Riccardo Dalla-Favera; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

7.  Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia.

Authors:  James S Blachly; Amy S Ruppert; Weiqiang Zhao; Susan Long; Joseph Flynn; Ian Flinn; Jeffrey Jones; Kami Maddocks; Leslie Andritsos; Emanuela M Ghia; Laura Z Rassenti; Thomas J Kipps; Albert de la Chapelle; John C Byrd
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-18       Impact factor: 11.205

Review 8.  Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

Authors:  Jan A Burger
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

9.  Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2.

Authors:  Angela Schulz; Grischa Toedt; Thorsten Zenz; Stephan Stilgenbauer; Peter Lichter; Martina Seiffert
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

Review 10.  Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.

Authors:  Sarah E M Herman; Amy J Johnson
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.